Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (β- L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4803-4810

  Kadhim, Salam A ^a   Bowlin, Terry L ^a   Waud, William R ^b   Angers, Elyzabeth G ^a   Bibeau, Lucie ^a   DeMuys, Jean Marc ^a   Bednarski, Krzysztof ^a   Cimpoia, Alex ^a   Attardo, Giorgio ^a  

^a Shire Canada   (Canada)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DIOXOLANE CYTIDINE; CISPLATIN; CYTARABINE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NUCLEOSIDE DERIVATIVE; TROXACITABINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; PRIORITY JOURNAL; STEREOCHEMISTRY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYTOSINE; DIOXOLANES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; NUCLEOSIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030775136     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Muss, H. B. Renal cell carcinoma. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Biological Therapy of Cancer, pp. 298-311. Philadelphia: J. B. Lippincott Co., 1991.
2. Myers, M. H., and Gloeckler, L. A. Cancer patient survival rate: SEER program results for 10 years of follow-up. CA, 39: 21-32, 1989.
3. Silvenberg, E., and Lubera, J. Cancer statistics. CA Cancer J. Clin., 2: , 1987.
4. Robertson, C. N., Linehan, W. M., Pass, H. I., Gomella, L. G., Hass, G. P., Berman, A., Merino, M., and Rosenberg, S. A. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine-activated killer cells. J. Urol., 144: 614-617, 1990.
5. Koch, I., Depenbrock, H., Danhauser-Riedel, S., Rastetter, J. W., and Hanauske, A. R. Interleukin-1 modulates growth of human renal carcinoma cells in vitro. Br. J. Cancer, 71: 794-8001, 1995.
6. Belldegrun, A., and Rosenberg, S. A. Adoptive immunotherapy of urologie tumors. Cancer Treat. Res., 46: 213-233, 1989.
7. Lotze, M. T., Custer, M. C., Bolton, E. S., Wiebke, E. A., Kawakami, Y., and Rosenberg, S. A. Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical application. Hum. Immunol., 28: 198-207, 1990.
8. Dutcher, J., Fisher, R., Weiss, G., Aronson, F., Margolin, K., Louie, A., and Atkins, M. Outpatient subcutaneous (sc) interleukin-2 (IL-2) plus α-interferon (IFN) in metastatic renal cell cancer (RCC): 3-year follow-up of the Cytokine Working Group Study. Am. Soc. Clin. Oncol., 14: 332, 1995.
9. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C. A., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., and White, D. E. Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863-1874, 1989.
10. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A., and White, D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474-485, 1989.
11. Wong, M. K., Bjarnason, G. A., Hrushesky, W. J., Webster, P., Morava-Protzner, I., and Towers, M. Steroid-responsive interstitial lung disease in patients receiving 2′-deoxy-5-fluorouridine-infusion chemotherapy: a report of three cases. Cancer (Phila.), 75: 2558-2564, 1995.
12. Baiocchi, C., Landonio, G., Cacioppo, C., Calgaro, M., Cattaneo, D., Ferrari, M., and Majno, M. Continuous non-chronomodulated infusion of floxuridine in metastatic renal cell carcinomas (MRCC): report of 17 cases. Tumori, 82: 225-227, 1996.
13. Carmichael, J., Fink, U., Russell, R. C., Spittle, M. F., Harris, A. L., Spiessi, G., and Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer, 73: 101-105, 1996.
14. Lund, B., Kristjansen, P. E. G., and Hansen, H. H. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat. Rev., 19: 45-55, 1993.
15. Rhode, D., DeMulder, P. H., Weissbac, L., Osieka, R., Blatter, J., and Jakse, G. Experimental and clinical efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) against renal cell carcinoma. Oncology (Basel), 53: 476-481, 1996.
16. DeMulder, P. H., Weissbach, L., Jakse, G., Osieka, R., and Blatter, J. Gemcitabine: a Phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol., 37: 491-495, 1996.
17. Mansour, T. S., Jin, H., Wang, W., Dixit, D. M., Evans, C. A., Tse, A. H. L., Belleau, B., Gillard, J. W., Hooker, E., Ashman, C., Cammack, N., Salomon, H., Belmonte, A. R., and Weinberg, M. A. Structure activity relationships among a new class of antiviral heterosubstituted 2′,3′-dideoxynucleoside analogues. Nucleosides Nucleotides, 14: 627-635, 1995.
18. Grove, K. L., and Cheng, Y. C. Uptake and metabolism of the new anticancer compound β-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res., 56: 4187-4191, 1996.
19. Grove, K. L., Guo, X., Liu, S-H., Gao, Z., Chu, C. K., and Cheng, Y. C. Anticancer activity of β-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res., 55: 3008-3011, 1995.
20. Kukhahova, M., Liu, S-H., Mozzherin, D., Lin, T-S., Chu, C. K., and Cheng, Y-C. L-and D-enantiomers of 2′,3′-dideoxycytidine-5′-triphosphate analogs as substrates for human DNA polymerases. J. Biol. Chem., 270: 23055-23059, 1995.
21. Ohno, Y., Spriggs, D., Marsukage, A., Ohno, T., and Kufe, D. Sequence-specific inhibition of DNA strand elongation by incorporation of 9-β-D-arabinofuranosyladenine. Cancer Res., 49: 2077-2081, 1989.
22. Bowlin, T. L., Genne, P., Kadhim, S. A., Gourdeau, H., and Attardo, G. A novel cytidine nucleoside analogue, BCH-4556, with potent activity against anthracycline-resistant leukemia. Proc. Am. Assoc. Cancer Res., 38: 100, 1997.
23. Attardo, G., Kadhim, S. A., Angers, E. M., Bibeau, L., and Bowlin, T. Dose scheduling effects on the antitumor activity of BCH-4556 against human xenografts in nude mice. Proc. Am. Assoc. Cancer Res., 38: 100, 1997.
24. Gourdeau, H., Attardo, G., Duchamp, O., Kadhim, S., Anger, E. M., and Genne, P. β-L-dioxolane cytidine (BCH-4556); a novel nucleoside analogue with antitumor effect against multidrug-resistant human tumors. In: Proceedings AACR Special Conference on Cell Signaling and Cancer Treatment, p. C-6, 1997.
25. Plumb, J. A., Milroy, R., and Kaye, S. B. Effects of the pH dependence of 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res., 49: 4435-4440, 1989.
26. 34cdc2 kinase activation in serum-stimulated human fibroblasts. J. Biol. Chem., 268: 138-145, 1993.
27. Bogden, A. E., Haskell, P. M., LePage, D. J., Kelton, D. E., Cobb, W. R., and Esber, H. J. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp. Cell. Biol., 47: 281-293, 1979.
28. Holland, J. M. Cancer of the kidney: natural history and staging. Cancer (Phila.), 32: 1030-1042, 1973.
29. Quesada, J. R., Swanson, D. A., and Gutterman, J. U. Phase II study of interferon α in metastatic renal cell carcinoma: a progress report. J. Clin. Oncol., 3: 1086-1092, 1985.
30. Kirkwood, J. M., Harris, J. E., Vera, R., . A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res., 863: 871, 1985.
31. Markowitz, A., Talpaz, M., and Lee, K. Phase I-II study of recombinant interleukin-α2A(γ2) plus recombinant interferon-α2a (γIFN-α) in renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol., 8: 146, 1989.
32. Beniers, A. J. M. C., Peleen, W. P., Hendriks, B. T., . Effect of α-and γ-interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. Semin. Surg. Oncol., 4: 195-198, 1988.
33. Miller, W. H., Jr., Reyno, L. M., Beare, S., Jaunakais, D., Loewen, G., Parker, B. A., Plitt, E., Truglia, J. A., and Eisenhauer, E. A. Phase I and pharmacokinetic (PK) study of 9-cis-retinoic acid (9cRA) and interferon-γ-2b (IFN) in advanced renal cell carcinoma. Proc. Am. Assoc. Cancer Res., 38: 86, 1997.
34. Fossa, S. D., and DeGaris, S. T. Further experience with recombinant interferon α-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer (Phila.), 57: 1700-1704, 1986.
35. Walder, S., Einzig, A. I., Dutcher, J. P., . Phase II trial of recombinant α-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma. Am. J. Clin. Oncol., 11: 55-59, 1988.
36. Muss, H. B., Welander, C., Caponera, M., . Interferon and doxorubicin in renal cell carcinoma. Cancer Treat. Res., 69: 721-722, 1985.
37. Bukowski, R., Rayman, P., Don, W., Sandstrom, K., McLain, D., Budd, G. T., Peerboom, D., Olencki, T., Novick, A., and Finke, J. 5FU, rIL-2, and IFNα therapy of metastatic renal cell carcinoma (RCCL modulation of T-cell signal transduction abnormalities). Proc. Am. Assoc. Cancer Res., 38: 431, 1997.
38. Quesada, J. R., Talpaz, M., Rios, A. Clinical toxicity of interferon in cancer patients: a review. J. Clin. Oncol., 4: 234-243, 1986.
39. Belldegrun, A., Webb, D. E., Austin, H. A., III, Steinberg, S. M., Linehan, W. M., and Rosenberg, S. A. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J. Urol., 141: 499-503, 1989.
40. Dykes, D. J., Abbot, B. J., Mayo, J. G., Harrison, S. D., Jr., Laster, W. R., Jr., Simpson-Herren, L., and Griswold, D. P., Jr. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib. Oncol., 42: 1-22, 1992.
41. Bogden, A. E., Kelton, D. E., Cobb, W. R., and Ebster, H. J. A rapid screening method for testing chemotherapeutic agents against human tumor xenografts. In: Houchens and Ovejera (eds.), Proc. Symp. on the Use of Antymic (Nude) Mice in Cancer Research, pp. 231-250. New York: Fisher, 1978.
42. th International Congress of Chemotherapy, Vol. 2, p. 1228, 1995.
43. Arner, E. S. J., Spasokouhotskaja, T., and Eriksson, S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun., 188: 712-718, 1992.